Richard A. King
Chief Executive Officer at Prolynx LLC
Richard A. King active positions
Companies | Position | Start | End |
---|---|---|---|
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Director/Board Member | 2022-09-19 | - |
Chief Executive Officer | 2022-09-19 | - |
Career history of Richard A. King
Former positions of Richard A. King
Companies | Position | Start | End |
---|---|---|---|
SPRUCE BIOSCIENCES, INC. | Director/Board Member | 2019-09-30 | 2021-10-14 |
Chief Executive Officer | 2019-09-30 | 2021-10-14 | |
ADAMAS PHARMACEUTICALS, INC. | Chief Operating Officer | 2017-04-27 | 2018-09-14 |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Chief Operating Officer | 2016-03-31 | 2017-03-31 |
TALPHERA, INC. | Director/Board Member | 2011-02-14 | 2014-11-04 |
Chief Executive Officer | 2010-04-30 | 2015-03-30 | |
President | 2010-04-30 | 2014-11-04 | |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | President | - | 2009-03-31 |
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | 2001-12-31 | 2006-08-31 |
Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Corporate Officer/Principal | 1999-12-31 | 2001-12-31 |
Unimed Pharmaceuticals LLC
Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1948 and was headquartered in Marietta, GA. | Corporate Officer/Principal | - | - |
░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Richard A. King
University of Surrey | Undergraduate Degree |
Manchester Business School | Masters Business Admin |
Statistics
International
United States | 11 |
United Kingdom | 3 |
Operational
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 3 |
Sectoral
Health Technology | 9 |
Consumer Services | 4 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
TALPHERA, INC. | Health Technology |
SPRUCE BIOSCIENCES, INC. | Health Technology |
Private companies | 7 |
---|---|
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Health Technology |
Cortria Corp.
Cortria Corp. Pharmaceuticals: MajorHealth Technology Cortria Corp. operates as a clinical-stage pharmaceutical company that focuses on developing medicines to fight cardiovascular disease. Its product is used for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. The company was founded in August 2005 and is headquartered in Needham, MA. | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Unimed Pharmaceuticals LLC
Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1948 and was headquartered in Marietta, GA. | Health Technology |
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Richard A. King
- Experience